244 related articles for article (PubMed ID: 18357378)
21. PUMA expression is significantly reduced in human cutaneous melanomas.
Karst AM; Dai DL; Martinka M; Li G
Oncogene; 2005 Feb; 24(6):1111-6. PubMed ID: 15690057
[TBL] [Abstract][Full Text] [Related]
22. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.
Massi D; Naldini A; Ardinghi C; Carraro F; Franchi A; Paglierani M; Tarantini F; Ketabchi S; Cirino G; Hollenberg MD; Geppetti P; Santucci M
Hum Pathol; 2005 Jun; 36(6):676-85. PubMed ID: 16021575
[TBL] [Abstract][Full Text] [Related]
23. A subgroup of melanocytic nevi on the distal lower extremity (ankle) shares features of acral nevi, dysplastic nevi, and melanoma in situ: a potential misdiagnosis of melanoma in situ.
Khalifeh I; Taraif S; Reed JA; Lazar AF; Diwan AH; Prieto VG
Am J Surg Pathol; 2007 Jul; 31(7):1130-6. PubMed ID: 17592281
[TBL] [Abstract][Full Text] [Related]
24. Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7--challenging the concept of dysplastic nevi as precursor lesions?
Decarlo K; Yang S; Emley A; Wajapeyee N; Green M; Mahalingam M
Hum Pathol; 2010 Jun; 41(6):886-94. PubMed ID: 20233623
[TBL] [Abstract][Full Text] [Related]
25. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
[TBL] [Abstract][Full Text] [Related]
26. Protein expression of melanocyte growth factors (bFGF, SCF) and their receptors (FGFR-1, c-kit) in nevi and melanoma.
Giehl KA; Nägele U; Volkenandt M; Berking C
J Cutan Pathol; 2007 Jan; 34(1):7-14. PubMed ID: 17214848
[TBL] [Abstract][Full Text] [Related]
27. Nuclear ING2 expression is reduced in human cutaneous melanomas.
Lu F; Dai DL; Martinka M; Ho V; Li G
Br J Cancer; 2006 Jul; 95(1):80-6. PubMed ID: 16755297
[TBL] [Abstract][Full Text] [Related]
28. Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma.
Prieto VG; Mourad-Zeidan AA; Melnikova V; Johnson MM; Lopez A; Diwan AH; Lazar AJ; Shen SS; Zhang PS; Reed JA; Gershenwald JE; Raz A; Bar-Eli M
Clin Cancer Res; 2006 Nov; 12(22):6709-15. PubMed ID: 17121890
[TBL] [Abstract][Full Text] [Related]
29. Bcl2 and Bax expression in naevi and melanomas and their relation to ploidy status and proliferation.
Korabiowska M; Brinck U; Ruschenburg I; Schlott T; Droese M; Stachura J
Pol J Pathol; 1999; 50(1):17-21. PubMed ID: 10412270
[TBL] [Abstract][Full Text] [Related]
30. Minichromosome maintenance proteins are useful adjuncts to differentiate between benign and malignant melanocytic skin lesions.
Gambichler T; Shtern M; Rotterdam S; Bechara FG; Stücker M; Altmeyer P; Kreuter A
J Am Acad Dermatol; 2009 May; 60(5):808-13. PubMed ID: 19389522
[TBL] [Abstract][Full Text] [Related]
31. Expression of heat shock protein 105 and 70 in malignant melanoma and benign melanocytic nevi.
Park HS; Park CH; Choi BR; Lim MS; Heo SH; Kim CH; Kang SG; Whang KU; Cho MK
J Cutan Pathol; 2009 May; 36(5):511-6. PubMed ID: 19476517
[TBL] [Abstract][Full Text] [Related]
32. Expression of CD44 variant isoforms in malignant melanoma.
Seiter S; Schadendorf D; Herrmann K; Schneider M; Rösel M; Arch R; Tilgen W; Zöller M
Clin Cancer Res; 1996 Mar; 2(3):447-56. PubMed ID: 9816190
[TBL] [Abstract][Full Text] [Related]
33. Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression.
Einspahr JG; Thomas TL; Saboda K; Nickolof BJ; Warneke J; Curiel-Lewandrowski C; Ranger-Moore J; Duckett L; Bangert J; Fruehauf JP; Alberts DS
Cancer; 2007 Dec; 110(11):2519-27. PubMed ID: 17932890
[TBL] [Abstract][Full Text] [Related]
34. IMP-3 EXPRESSION IN BENIGN MELANOCYTIC NEVI, DYSPLASTIC NEVI AND MALIGNANT MELANOMA: PRELIMINARY FINDINGS IN BULGARIAN PATIENTS.
Chokoeva AA; Ananiev J; Wollina U; Tana C; Lotti T; Cardoso JC; Tchernev G
J Biol Regul Homeost Agents; 2015; 29(3):695-9. PubMed ID: 26403409
[TBL] [Abstract][Full Text] [Related]
35. Antigen Ki-67 and c-myc oncogene as related to histoclinical parameters in pigmented skin lesions.
Korabiowska M; Brinck U; Mirecka J; Kellner S; Marx D; Schauer A
In Vivo; 1995; 9(5):433-8. PubMed ID: 8900920
[TBL] [Abstract][Full Text] [Related]
36. Actin-binding protein expression in benign and malignant melanocytic proliferations.
Bouffard D; Duncan LM; Howard CA; Mihm MC; Byers HR
Hum Pathol; 1994 Jul; 25(7):709-14. PubMed ID: 8026830
[TBL] [Abstract][Full Text] [Related]
37. Decreased expression of retinoid receptors in melanoma: entailment in tumorigenesis and prognosis.
Chakravarti N; Lotan R; Diwan AH; Warneke CL; Johnson MM; Prieto VG
Clin Cancer Res; 2007 Aug; 13(16):4817-24. PubMed ID: 17699860
[TBL] [Abstract][Full Text] [Related]
38. Oestrogen receptor-beta expression in melanocytic lesions.
Schmidt AN; Nanney LB; Boyd AS; King LE; Ellis DL
Exp Dermatol; 2006 Dec; 15(12):971-80. PubMed ID: 17083364
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of nuclear ING3 expression in human cutaneous melanoma.
Wang Y; Dai DL; Martinka M; Li G
Clin Cancer Res; 2007 Jul; 13(14):4111-6. PubMed ID: 17634537
[TBL] [Abstract][Full Text] [Related]
40. The significance of Ki-67 proliferative index and cyclin D1 expression of dysplastic nevi in the biologic spectrum of melanocytic lesions.
Lebe B; Pabuççuoğlu U; Ozer E
Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):160-4. PubMed ID: 17525627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]